Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.

about

Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.

Item

http://www.wikidata.org/entity/Q51043340

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@en

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@nl

type

Item

label

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@en

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@nl

prefLabel

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@en

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@nl

P1476

Antihyperglycemic effect of ip ...... al antidiabetic drugs in mice.

@en

P2093

Atsuo Tahara

http://www.w3.org/2001/XMLSchema#string

Eiji Kurosaki

http://www.w3.org/2001/XMLSchema#string

Shoji Takakura

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Takasu

http://www.w3.org/2001/XMLSchema#string

Yuka Hayashizaki

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

SGLT2 mediates glucose reabsorption in the early proximal tubule.

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

P304

87-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1440-1681.12317

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25311502

http://www.w3.org/2001/XMLSchema#string